1982Current Medical Research and OpinionRequires access

The treatment of hypertension in pregnancy

M. Peter Moore, Christopher W.G. Redman

Open publisher page 20 citations

Abstract

SummaryThe rationale for the drug treatment of severe maternal hypertension occurring concurrently with or induced by pregnancy is discussed. Methyldopa is the antihypertensive agent most commonly used at present in pregnancy but recently the use of beta-blocking drugs and the combined alpha-blocker and beta-blocker labetalol has been advocated. Interim results from 74 patients in an ongoing randomized trial comparing methyldopa (1. 0 to 4.0 g/day) with labetalol (0.3 to 1.2 g/day) indicate that the two drugs have an equivalent antihypertensive effect and both cause side-effects. There is no evidence that either drug significantly altered the progression of established pre-eclampsia.

About this research paper

What this paper is about

SummaryThe rationale for the drug treatment of severe maternal hypertension occurring concurrently with or induced by pregnancy is discussed. Methyldopa is the antihypertensive agent most commonly used at present in pregnancy but recently the use of beta-blocking drugs and the combined alpha-blocker and beta-blocker labetalol has been advocated. Interim results from 74 patients in an ongoing randomized trial comparing methyldopa (1. 0 to 4.0 g/day) with labetalol (0.3 to 1.2 g/day) indicate that the two drugs have an equivalent antihypertensive effect and both cause side-effects. There is no evidence that either drug significantly altered the progression of established pre-eclampsia.

Why it matters

OpenAlex reports 20 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

SummaryThe rationale for the drug treatment of severe maternal hypertension occurring concurrently with or induced by pregnancy is discussed. Methyldopa is the antihypertensive agent most commonly used at present in pregnancy but recently the use of beta-blocking drugs and the combined alpha-blocker and beta-blocker labetalol has been advocated. Interim results from 74 patients in an ongoing randomized trial comparing methyldopa (1. 0 to 4.0 g/day) with labetalol (0.3 to 1.2 g/day) indicate that the two drugs have an equivalent antihypertensive effect and both cause side-effects. There is no evidence that either drug significantly altered the progression of established pre-eclampsia.

Key concepts: Labetalol, Medicine, Methyldopa, Pregnancy, Hypertension in Pregnancy, Eclampsia, Drug, Randomized controlled trial

Related papers

Back to paper searchBrowse research topicsOriginal source
The treatment of hypertension in pregnancy — Research Paper | ScholarLens